Bionexus Gene LabBGLC
13F holders, Q3 2024 (September 30)4holders +1
3new positions
2sold out
$0.45avg. 13F price*
At the end of Q3 2024, 4 institutions reported holding Bionexus Gene Lab Corp. (BGLC) in their 13F filings, up 1 from Q2 2024. 3 opened new positions and 2 sold out. The largest holders were UBS Group AG ($37K), Geode Capital Management, LLC ($11K) and Cambridge Investment Research Advisors, Inc. ($6K).
- Company
- Bionexus Gene Lab Corp.
- CUSIP
- 090628207
- Latest filing quarter
- Q1 2025
History
Number of 13F holders
Total Exit/New Position Q2 2024 → Q3 2024
| Institutions | Total Value | |
|---|---|---|
| New Positions | 3 | $48K |
| Exits | 2 | $19K |
All 13F filers, Q2 2024 → Q3 2024: 106,653 shares bought and 42,044 shares sold, net +64,609 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 4 holders
| UBS Group AG | 0.00% | New | 83,308 | $37K |
| Geode Capital Management, LLC | 0.00% | No change | 23,681 | $11K |
| Cambridge Investment Research Advisors, Inc. | 0.00% | New | 12,960 | $6K |
| Scientech Research LLC | 0.00% | New | 10,385 | $5K |
"% of holder's portfolio" is BGLC's weight in each manager's 13F, not the share of Bionexus Gene Lab Corp. the manager owns.